<p>即使一家公司在亏损，股东也有可能通过以合适的价格购买优质企业而获利。例如，尽管亚马逊在上市后多年亏损，但如果你从 1999 年开始购买并持有其股票，你将获得丰厚的回报。话虽如此，亏损公司是有风险的，因为它们可能会耗尽所有现金并陷入困境。</p>
<p>鉴于这种风险，我们认为有必要看看 <strong>Zentalis Pharmaceuticals</strong>（纳斯达克：ZNTL）的股东是否应该担心其现金消耗。为了本文的目的，我们将现金消耗定义为公司每年为支持其增长而支出的现金金额（也称为负自由现金流）。让我们先来审视一下该公司的现金与其现金消耗的关系。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<h2>Zentalis Pharmaceuticals 的现金储备是否充足？</h2>
<p>现金储备被定义为公司在保持当前现金消耗率的情况下，耗尽资金所需的时间。到 2025 年 6 月，Zentalis Pharmaceuticals 拥有 3.03 亿美元的现金，并且没有债务。在过去一年中，其现金消耗为 1.51 亿美元。因此，从 2025 年 6 月起，它的现金储备大约为 2.0 年。可以说，这是一段谨慎且合理的资金储备时间。你可以在下面的图像中看到其现金余额随时间的变化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/647536411-debt-equity-history-analysis-1-dark-2/1755346131330?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/647536411-debt-equity-history-analysis-1-dark-2/1755346131330"/></p>
<p>纳斯达克 GM:ZNTL 债务与股本历史 2025 年 8 月 16 日</p>
<p>查看我们对 Zentalis Pharmaceuticals 的最新分析</p>
<h2>Zentalis Pharmaceuticals 的增长情况如何？</h2>
<p>Zentalis Pharmaceuticals 在过去一年中将其现金消耗减少了 9.5%，这表明其在某种程度上具有一定的自律性。但在同一时期，收入下降了 34%，这让人有些担忧。综合来看，我们认为这些增长指标有些令人担忧。然而，关键因素显然是公司未来是否能够实现业务增长。因此，查看我们对该公司的分析师预测是非常有意义的。</p>
<h2>Zentalis Pharmaceuticals 筹集现金的难易程度如何？</h2>
<p>虽然 Zentalis Pharmaceuticals 似乎处于相对良好的位置，但仍值得考虑它能多容易地筹集更多现金，即使只是为了加速增长。发行新股或承担债务是上市公司为其业务筹集更多资金的最常见方式。通常，一家公司会出售新股以筹集现金并推动增长。通过查看公司的现金消耗与其市值的关系，我们可以洞察如果公司需要筹集足够的现金来覆盖另一年的现金消耗，股东将面临多大的稀释。</p>
<p>Zentalis Pharmaceuticals 的市值为 1.07 亿美元，而去年消耗了 1.51 亿美元，这相当于公司市值的 142%。考虑到这一支出相对于公司市值的高额，我们认为存在较高的资金困境风险，我们对持有该股票感到非常紧张。</p>
<h2>Zentalis Pharmaceuticals 的现金消耗是否令人担忧？</h2>
<p>尽管其现金消耗相对于市值让我们有些紧张，但我们不得不提到，我们认为 Zentalis Pharmaceuticals 的现金储备相对乐观。在考虑了这一系列指标后，我们认为股东应该非常关注公司如何使用其现金，因为现金消耗让我们感到不安。对风险的深入审查揭示了 <strong>Zentalis Pharmaceuticals 的 1 个警示信号</strong>，读者在投入资金之前应考虑这一点。</p>
<p>当然，<strong>你可能会在其他地方找到一个绝佳的投资机会。</strong> 所以请查看这份 <strong>免费</strong> 的公司内部持股显著的名单，以及这份根据分析师预测的成长股名单。</p>

ZNTL

<p>Zentalis Pharmaceuticals（纳斯达克代码：ZNTL）面临着现金消耗为 1.51 亿美元，而市值仅为 1.07 亿美元的挑战，这表明可能存在融资困境。尽管现金消耗减少了 9.5%，但令人担忧的是收入下降了 34%，这引发了对未来增长的质疑。该公司的现金储备大约可以支撑 2 年，这被认为是谨慎的。然而，如果公司需要筹集额外资金，股东应对稀释风险的上升保持警惕。总体而言，尽管有一些积极因素，但现金消耗的情况值得投资者密切关注</p>

<p>Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.</p>
<div class="lb-trans"><p>即使一家公司在亏损，股东也有可能通过以合适的价格购买优质企业而获利。例如，尽管亚马逊在上市后多年亏损，但如果你从 1999 年开始购买并持有其股票，你将获得丰厚的回报。话虽如此，亏损公司是有风险的，因为它们可能会耗尽所有现金并陷入困境。</p>
</div><p>Given this risk, we thought we'd take a look at whether <strong>Zentalis Pharmaceuticals</strong> (NASDAQ:ZNTL) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn.</p>
<div class="lb-trans"><p>鉴于这种风险，我们认为有必要看看 <strong>Zentalis Pharmaceuticals</strong>（纳斯达克：ZNTL）的股东是否应该担心其现金消耗。为了本文的目的，我们将现金消耗定义为公司每年为支持其增长而支出的现金金额（也称为负自由现金流）。让我们先来审视一下该公司的现金与其现金消耗的关系。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><h2>Does Zentalis Pharmaceuticals Have A Long Cash Runway?</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 的现金储备是否充足？</h2>
</div><p>A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In June 2025, Zentalis Pharmaceuticals had US$303m in cash, and was debt-free. In the last year, its cash burn was US$151m. So it had a cash runway of about 2.0 years from June 2025. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below.</p>
<div class="lb-trans"><p>现金储备被定义为公司在保持当前现金消耗率的情况下，耗尽资金所需的时间。到 2025 年 6 月，Zentalis Pharmaceuticals 拥有 3.03 亿美元的现金，并且没有债务。在过去一年中，其现金消耗为 1.51 亿美元。因此，从 2025 年 6 月起，它的现金储备大约为 2.0 年。可以说，这是一段谨慎且合理的资金储备时间。你可以在下面的图像中看到其现金余额随时间的变化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/647536411-debt-equity-history-analysis-1-dark-2/1755346131330" alt="" original-src="https://images.simplywall.st/asset/chart/647536411-debt-equity-history-analysis-1-dark-2/1755346131330"/></p>
<p>NasdaqGM:ZNTL Debt to Equity History August 16th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:ZNTL 债务与股本历史 2025 年 8 月 16 日</p>
</div><p>See our latest analysis for Zentalis Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 Zentalis Pharmaceuticals 的最新分析</p>
</div><h2>How Well Is Zentalis Pharmaceuticals Growing?</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 的增长情况如何？</h2>
</div><p>Zentalis Pharmaceuticals reduced its cash burn by 9.5% during the last year, which points to some degree of discipline. But the revenue dip of 34% in the same period was a bit concerning. Taken together, we think these growth metrics are a little worrying. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals 在过去一年中将其现金消耗减少了 9.5%，这表明其在某种程度上具有一定的自律性。但在同一时期，收入下降了 34%，这让人有些担忧。综合来看，我们认为这些增长指标有些令人担忧。然而，关键因素显然是公司未来是否能够实现业务增长。因此，查看我们对该公司的分析师预测是非常有意义的。</p>
</div><h2>How Easily Can Zentalis Pharmaceuticals Raise Cash?</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 筹集现金的难易程度如何？</h2>
</div><p>While Zentalis Pharmaceuticals seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.</p>
<div class="lb-trans"><p>虽然 Zentalis Pharmaceuticals 似乎处于相对良好的位置，但仍值得考虑它能多容易地筹集更多现金，即使只是为了加速增长。发行新股或承担债务是上市公司为其业务筹集更多资金的最常见方式。通常，一家公司会出售新股以筹集现金并推动增长。通过查看公司的现金消耗与其市值的关系，我们可以洞察如果公司需要筹集足够的现金来覆盖另一年的现金消耗，股东将面临多大的稀释。</p>
</div><p>Zentalis Pharmaceuticals has a market capitalisation of US$107m and burnt through US$151m last year, which is 142% of the company's market value. Given just how high that expenditure is, relative to the company's market value, we think there's an elevated risk of funding distress, and we would be very nervous about holding the stock.</p>
<div class="lb-trans"><p>Zentalis Pharmaceuticals 的市值为 1.07 亿美元，而去年消耗了 1.51 亿美元，这相当于公司市值的 142%。考虑到这一支出相对于公司市值的高额，我们认为存在较高的资金困境风险，我们对持有该股票感到非常紧张。</p>
</div><h2>Is Zentalis Pharmaceuticals' Cash Burn A Worry?</h2>
<div class="lb-trans"><h2>Zentalis Pharmaceuticals 的现金消耗是否令人担忧？</h2>
</div><p>Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Zentalis Pharmaceuticals' cash runway was relatively promising. After looking at that range of measures, we think shareholders should be extremely attentive to how the company is using its cash, as the cash burn makes us uncomfortable. An in-depth examination of risks revealed <strong>1 warning sign for Zentalis Pharmaceuticals</strong> that readers should think about before committing capital to this stock.</p>
<div class="lb-trans"><p>尽管其现金消耗相对于市值让我们有些紧张，但我们不得不提到，我们认为 Zentalis Pharmaceuticals 的现金储备相对乐观。在考虑了这一系列指标后，我们认为股东应该非常关注公司如何使用其现金，因为现金消耗让我们感到不安。对风险的深入审查揭示了 <strong>Zentalis Pharmaceuticals 的 1 个警示信号</strong>，读者在投入资金之前应考虑这一点。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)</p>
<div class="lb-trans"><p>当然，<strong>你可能会在其他地方找到一个绝佳的投资机会。</strong> 所以请查看这份 <strong>免费</strong> 的公司内部持股显著的名单，以及这份根据分析师预测的成长股名单。</p>
</div>

ZeZentalis Pharma（纳斯达克股票代码：ZNTL）是否具备良好的条件来实现其增长计划？